Reig Jofre
Reig Jofre is a Barcelona-based, publicly listed Spanish pharmaceutical company that develops, manufactures, and distributes specialty prescription medicines (antibiotics, biosimilars, hospital injectables, dermatology) and consumer health brands (Forté Pharma, Sterimar) across more than seven European markets and selected export geographies including Japan and China.
- Company typePublic
- Founded1929
- HeadquartersBarcelona, Spain
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Reig Jofre does
Reig Jofre (Laboratorio Reig Jofre, S.A.) is a Barcelona-headquartered, publicly listed Spanish pharmaceutical company founded in 1929. It develops, manufactures, markets, and distributes essential healthcare solutions spanning prescription specialty pharmaceuticals — antibiotics, hospital injectables, biosimilars, dermatology, women's health, and pediatrics — and consumer health brands including Forté Pharma (nutraceuticals), Sterimar (nasal hygiene), VINCOBIOSIS®, Regenail®, and Triferty-ATM®. The company operates a vertically integrated model combining R&D, sterile injectable manufacturing at its Toledo antibiotics plant, biopharmaceutical capabilities through the Syna Therapeutics joint venture with LeanBio (formed 2018, fully acquired December 2025), and a multi-country European commercial footprint via wholly-owned subsidiaries in Sweden (Bioglan), Poland, the Czech Republic, the United Kingdom, France, Portugal, and Italy.
The core technology platform rests on specialized pharmaceutical manufacturing — sterile injectables, beta-lactam antibiotics, and biosimilars — augmented by biotechnology capabilities via Syna Therapeutics and participation in EU-designated vaccine production capacity alongside Zendal. Reig Jofre's go-to-market is hybrid: enterprise field sales to hospitals, prescribers, and public health systems for its prescription portfolio; pharmacy, parapharmacy, and wholesale distribution for consumer health brands; and CDMO/licensing partnerships with companies such as Stada (Parkinson's manufacturing capacity at Bioglan) and LEO Pharma (psoriasis primary-care access from March 2025). The company maintains an own e-commerce channel for Forté Pharma (including in China) and a branded pharmacy-banner channel ("Reig Jofre Farmacias") in Spain.
Revenue is generated primarily through unit-priced sales of pharmaceutical SKUs at B2B distribution and pharmacy retail, supplemented by CDMO/licensing royalties and consumer brand sales. Reig Jofre was admitted to Spain's IBEX Small Cap index in June 2024 and is governed under Spanish public-company disclosure rules with CNMV filings, a scrip dividend program, and a liquidity contract with Solventis. Operational scale benchmarks include 15 million vials of intravenous anesthetic supplied to Japan, 2023 results of 17% revenue growth and 15% EBITDA growth, and a €13 million CDTI Innovación grant awarded in May 2025 under the EU IPCEI Med4Cure project for advanced therapy manufacturing infrastructure. The company employs between 1,001 and 5,000 people.
Reig Jofre firmographics
Firmographics- Name
- Reig Jofre
- Legal name
- LABORATORIO REIG JOFRÉ, S.A.
- Website
- https://reigjofre.com
- Company type
- Public
- Founded year
- 1929
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Reig Jofre is a Barcelona-based, publicly listed Spanish pharmaceutical company that develops, manufactures, and distributes specialty prescription medicines (antibiotics, biosimilars, hospital injectables, dermatology) and consumer health brands (Forté Pharma, Sterimar) across more than seven European markets and selected export geographies including Japan and China.
- Ownership category
- akta.pro rank
Reig Jofre industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Reig Jofre is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Reig Jofre business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Specialty pharmaceutical product sales: Core revenue from sale of prescription specialty pharmaceuticals — antibiotics, hospital injectables, biosimilars, dermatology, women's health, and pediatrics — distributed through pharmacy networks, hospitals, and public health systems across Europe and selected international markets (e.g., anesthetic vials to Japan).
- Consumer health & nutraceuticals (Forté Pharma and own-brand supplements): Revenue from sale of consumer health, dietary supplement and preventive-care brands (Forté Pharma, Sterimar and related lines) through pharmacy, parapharmacy, and own e-commerce storefronts targeting end consumers.
- CDMO / industrial manufacturing and licensing services: Revenue from contract manufacturing, industrial development, and licensing services — including the Bioglan (Sweden) Parkinson's treatment capacity built for Stada (2021) and inclusion in EU-designated vaccine manufacturing capacity with Zendal (2023).
- Biosimilar R&D and co-development (Syna Therapeutics): Revenue and equity participation from the 2018 Syna Therapeutics joint venture with LeanBio for biosimilar development, manufacturing and commercialization, plus R&D services rendered through academic and EU-funded programs (University of Santiago de Compostela, Med4Cure/IPCEI).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | — | Pharmaceutical products priced per unit/SKU at B2B distribution and pharmacy retail (not publicly disclosed) |
| Unit Pricing | — | Consumer health and Forté Pharma SKUs priced per unit at retail and online |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
Reig Jofre product offering
Product offeringCore offering
Reig Jofre develops, produces, markets, and distributes essential healthcare solutions across prescription specialty pharmaceuticals (antibiotics, sterile injectables, biosimilars, hospital anti-infectives, dermatology, women's health, and pediatrics) and consumer health/nutraceutical brands (Forté Pharma, Sterimar, VINCOBIOSIS, Regenail, Triferty-ATM). The company also offers CDMO and licensing services through subsidiaries such as Bioglan (Sweden) and the Syna Therapeutics biosimilars joint venture, with EU-designated vaccine production capacity alongside Zendal.
Product overview
Reig Jofre operates a brand-and-subsidiary portfolio architecture rather than a single unified software product. The core platform is the Laboratorio Reig Jofre pharmaceutical manufacturing and distribution business, which develops, produces, markets and distributes essential healthcare solutions. This core is flanked by acquired sub-brands and consumer-health brands (Forté Pharma food supplements, Sterimar nasal hygiene, VINCOBIOSIS® dermatology, Reig Jofre Farmacias pharmacy channel, Regenail® and TRIFERTY-ATM® specialty products, and the Bioglan / Reig Jofre Sweden dermatology-and-Parkinson subsidiary). Advanced and biosimilar capabilities are operated through the Syna Therapeutics joint venture with LeanBio (biosimilars, including the LB-0702 license), and through the EMINTECH advanced-therapies initiative funded under the EU IPCEI Med4Cure program. The Reig Jofre Online Store (Tienda Online) serves as a consumer/employee channel for the portfolio. The product_overview reflects a multi-brand, multi-subsidiary pharmaceutical company; the named products above represent the actual portfolio captured.
Differentiator
Problem solved
Functional benefit
Brands
- FORTÉ PHARMA Laboratoires: Brand of dietary supplements / nutritional complements operated by Reig Jofre group, with e-commerce presence including in China.
- STERIMAR
- REIG JOFRE Farmacias
- Vincobiosis (VINCOBIOSIS®)
- Bioglan
Products and services
- Reig Jofre Pharmaceutical Portfolio (essential healthcare solutions) Core offering: development, manufacturing, marketing and distribution of essential healthcare solutions ranging from critical, specialized treatments to preventive care across all stages of patients' lives. Includes prescription pharmaceuticals, sterile injectables, antibiotics and hospital specialty products for healthcare professionals and patients.
- Forté Pharma Reig Jofre's food supplements and nutricosmetics brand (Forté Pharma Laboratoires), marketed internationally including via e-commerce in China, for end consumers seeking dietary supplements and preventive care products.
- Sterimar
Quantifiable outcome
- 17% revenue growth and 15% EBITDA growth in 2023
- +3 more outcomes
Companies that use Reig Jofre
Customer profileSegments5 records
Ideal customer profiles4 records
Reig Jofre technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Reig Jofre partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship, core and minor.
- LEO PharmaflagshipPartnership announced in March 2025 to improve access to psoriasis treatment in primary care. Combines Reig Jofre's specialty pharma and biosimilar capabilities with LEO Pharma's dermatology franchise to broaden patient access to psoriasis therapies outside of specialist hospital settings.
- LeanBiocoreLong-standing biotech partner of Reig Jofre. Co-founded the Syna Therapeutics biosimilars joint venture in 2018 and received a €5.8M capital injection from Reig Jofre in 2024 to reinforce biosimilar development and biotech integration.
- ZendalcoreReig Jofre was designated alongside Zendal by the European Union in 2023 to provide vaccine production capacity, supporting EU pandemic preparedness and reinforcing Reig Jofre's vaccine manufacturing footprint.
- StadacorePartnership established in 2021 through Bioglan (Reig Jofre's Swedish subsidiary) to add manufacturing capacity for a Parkinson's disease treatment, strengthening Reig Jofre's CDMO offering for neurology and central nervous system therapies.
- VaxdynminorParticipation in the Vaxdyn vaccine biologicals development consortium from 2020, contributing to Reig Jofre's positioning in vaccine R&D and subsequent EU designation for vaccine production capacity.
- Syna TherapeuticsflagshipJoint venture established in 2018 between Reig Jofre and LeanBio to develop, manufacture and commercialize biosimilars. Syna Therapeutics is Reig Jofre's primary vehicle for proprietary biotech and biosimilar pipeline assets.
- University of Santiago de CompostelaminorAcademic collaboration for the development of the Dexulac product, leveraging the university's research capabilities in joint R&D with Reig Jofre's pharmaceutical innovation teams.
- Med4Cure / IPCEI HealthcoreEuropean consortium project (Important Project of Common European Interest in the Health sector) in which Reig Jofre participates to build advanced therapy manufacturing infrastructure, supported by a €13 million CDTI Innovación grant awarded in 2025.
- FarmaindustriaminorMembership in Farmaindustria, the Spanish pharmaceutical industry association, supporting sector advocacy, policy engagement, and industry visibility for Reig Jofre in Spain.
- AESEG
Scale indicators6 records
Recent moves8 records
Expansion highlights7 records
Reig Jofre competitors and assessment
Company assessmentDirect peers
- Faes Farma: Spanish specialty pharmaceutical company with OTC, prescription pharma and consumer health/nutraceutical brands. Directly comparable business mix to Reig Jofre's specialty pharma + Forté Pharma supplement portfolio.
- Zendal: Spanish biotechnology group focused on veterinary and human vaccines, designated alongside Reig Jofre by the EU in 2023 for vaccine production capacity. Closely comparable in pandemic-preparedness positioning and vaccine manufacturing scope.
- Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty products, listed in Barcelona. Closely comparable to Reig Jofre as a mid-cap Iberian pharma with dermatology franchises, hospital presence and pan-European commercialization.
- Laboratorios Rovi: Spanish specialty pharmaceutical company with proprietary manufacturing, biosimilars and CDMO services (Rovi Contract Manufacturing). Comparable as a mid-cap Iberian pharma with sterile injectable capacity and biosimilar strategy.
- Kern Pharma: Spanish generics and biosimilars subsidiary of Aurobindo. Comparable Spanish pharma with hospital tender exposure, biosimilar pipeline and pan-European distribution through parent group.
- Zambon: Italian privately-held specialty pharmaceutical company with branded prescription pharma and a CDMO business (Zambon Pharma). Comparable European mid-cap specialty pharma with similar international footprint.
Regional players
- Polpharma: Polish pharmaceutical manufacturer and one of the largest generics producers in Central Europe. Comparable as a regional European specialty/generics player relevant to Reig Jofre's Polish and Czech subsidiary markets.
Broad incumbents
- Hikma Pharmaceuticals: Listed mid-cap specialty pharma with generics, injectables and biosimilars across Europe, MENA and the US. Comparable business model mix and scale ambition to Reig Jofre's specialty + biosimilar + CDMO strategy.
- Stada Arzneimittel: Large European generics and specialty pharma group. Already a commercial partner of Reig Jofre via the Bioglan Parkinson's capacity deal (2021) and a benchmark for the type of scaled European specialty pharma Reig Jofre is moving toward.
- LEO Pharma: Global dermatology-focused pharmaceutical company headquartered in Denmark. Partner of Reig Jofre since March 2025 for psoriasis treatment access in primary care, providing a comparable dermatology specialty-pharma business model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Reig Jofre social profiles
Digital presenceReig Jofre compliance and trust
Trust signalCompliance4 records
Reig Jofre financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reig Jofre leadership team
Management profileNumber of profiles
Profiles4 records
Reig Jofre subsidiaries and ownership
Company hierarchySubsidiaries6 records
Reig Jofre funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reig Jofre M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reig Jofre
What does Reig Jofre do?
Reig Jofre develops, produces, markets, and distributes essential healthcare solutions across prescription specialty pharmaceuticals (antibiotics, sterile injectables, biosimilars, hospital anti-infectives, dermatology, women's health, and pediatrics) and consumer health/nutraceutical brands (Forté Pharma, Sterimar, VINCOBIOSIS, Regenail, Triferty-ATM). The company also offers CDMO and licensing services through subsidiaries such as Bioglan (Sweden) and the Syna Therapeutics biosimilars joint venture, with EU-designated vaccine production capacity alongside Zendal.
Is Reig Jofre a public or private company?
Reig Jofre is a public company. It is classified as public and is currently operating.
When was Reig Jofre founded?
Reig Jofre was founded in 1929. It employs 1,001 to 5,000 people.
Where is Reig Jofre based?
Reig Jofre is headquartered in Barcelona, Spain, in the Europe region.
How does Reig Jofre make money?
Four revenue lines are on record. Specialty pharmaceutical product sales are the primary driver. The others are consumer health & nutraceuticals (Forté Pharma and own-brand supplements), CDMO / industrial manufacturing and licensing services and biosimilar R&D and co-development (Syna Therapeutics).
Who are Reig Jofre's main competitors?
Direct peers on record are Faes Farma, Zendal, Almirall, Laboratorios Rovi, Kern Pharma and Zambon. Polpharma is listed as a regional player. Broad incumbents are Hikma Pharmaceuticals, Stada Arzneimittel and LEO Pharma.
Does Reig Jofre have an API?
No public API is recorded for Reig Jofre.
What industry is Reig Jofre in?
Reig Jofre's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.